Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer.

Autor: Shiota M; Department of Urology, Kyushu University, Fukuoka, Japan., Terada N; Department of Urology, Miyazaki University, Miyazaki, Japan., Kitamura H; Department of Urology, Graduate School of Medicine and Pharmaceutical Sciences for Research, University of Toyama, Toyama, Japan., Kojima T; Department of Urology, University of Tsukuba Hospital, Tsukuba, Japan., Saito T; Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan., Yokomizo A; Department of Urology, Harasanshin Hospital, Fukuoka, Japan., Kohei N; Department of Urology, Shizuoka General Hospital, Shizuoka, Japan., Goto T; Department of Urology, Kyoto University, Kyoto, Japan., Kawamura S; Department of Urology, Miyagi Cancer Center, Natori, Japan., Hashimoto Y; Department of Urology, Hirosaki University, Hirosaki, Japan., Takahashi A; Department of Urology, Hakodate Goryokaku Hospital, Hakodate, Japan., Kimura T; Department of Urology, Jikei University, Tokyo, Japan., Tabata KI; Department of Urology, Kitasato University, Sagamihara, Japan., Tomida R; Department of Urology, Shikoku Cancer Center, Matsuyama, Japan., Hashimoto K; Department of Urology, Sapporo Medical University, Sapporo, Japan., Sakurai T; Department of Urology, Yamagata University, Yamagata, Japan., Shimazui T; Department of Urology, Ibaraki Prefectural Central Hospital, Ibaraki Cancer Center, Kasama, Japan., Sakamoto S; Department of Urology, Chiba University, Chiba, Japan., Kamiyama M; Department of Urology, University of Yamanashi Hospital, Chuo, Japan., Tanaka N; Department of Urology, Nara Medical University, Kashihara, Japan., Mitsuzuka K; Department of Urology, Tohoku University, Sendai, Japan., Kato T; Department of Urology, Kagawa University, Kagawa, Japan., Narita S; Department of Urology, Akita University, Akita, Japan., Yasumoto H; Department of Urology, Shimane University, Izumo, Japan., Teraoka S; Department of Urology, Tottori University, Yonago, Japan., Kato M; Department of Urology, Nagoya University, Nagoya, Japan., Osawa T; Department of Renal and Genitourinary Surgery, Hokkaido University, Sapporo, Japan., Nagumo Y; Department of Urology, University of Tsukuba Hospital, Tsukuba, Japan., Matsumoto H; Department of Urology, Yamaguchi University, Ube, Japan., Enokida H; Department of Urology, Kagoshima University, Kagoshima, Japan., Sugiyama T; Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan., Kuroiwa K; Department of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan., Inoue T; Department of Nephro-Urologic Surgery and Andrology, Mie University Graduate School of Medicine, Tsu, Japan., Sugimoto M; Department of Urology, Kagawa University, Kagawa, Japan., Mizowaki T; Department of Radiation Oncology & Image-applied Therapy, Kyoto University, Kyoto, Japan., Kamoto T; Department of Urology, Miyazaki University, Miyazaki, Japan., Nishiyama H; Department of Urology, University of Tsukuba Hospital, Tsukuba, Japan., Eto M; Department of Urology, Kyushu University, Fukuoka, Japan.
Jazyk: angličtina
Zdroj: Cancer science [Cancer Sci] 2021 Sep; Vol. 112 (9), pp. 3616-3626. Date of Electronic Publication: 2021 Jul 10.
DOI: 10.1111/cas.15038
Abstrakt: The metastatic burden is a critical factor for decision-making in the treatment of metastatic hormone-sensitive prostate cancer (HSPC). This study aimed to develop and validate a novel risk model for survival in patients with de novo low- and high-burden metastatic HSPC. The retrospective observational study included men with de novo metastatic prostate cancer who were treated with primary androgen-deprivation therapy at 30 institutions across Japan between 2008 and 2017. We created a risk model for overall survival (OS) in the discovery cohort (n = 1449) stratified by the metastatic burden (low vs high) and validated its predictive ability in a separate cohort (n = 951). Based on multivariate analyses, lower hemoglobin levels, higher Gleason grades, and higher clinical T-stage were associated with poor OS in low-burden disease. Meanwhile, lower hemoglobin levels, higher Gleason grade group, liver metastasis, and higher extent of disease scores in bone were associated with poor OS in patients with high-burden disease. In the discovery and validation cohorts, the risk model using the aforementioned parameters exhibited excellent discriminatory ability for progression-free survival and OS. The predictive ability of this risk model was superior to that of previous risk models. Our novel metastatic burden-stratified risk model exhibited excellent predictive ability for OS, and it is expected to have several clinical uses, such as precise prognostic estimation.
(© 2021 The Authors. Cancer Science published by John Wiley & Sons Australia, Ltd on behalf of Japanese Cancer Association.)
Databáze: MEDLINE
Externí odkaz: